<DOC>
	<DOCNO>NCT02396966</DOCNO>
	<brief_summary>The purpose protocol evaluate describe QoL , population Polish acromegalic patient treat Lanreotide Autogel® 120 mg 24 month ( long term observation ) .</brief_summary>
	<brief_title>Quality Life ( QoL ) Subjects With Acromegaly Under Lanreotide Autogel® Treatment .</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<criteria>Adult patient acromegaly treat least three month longer three year Lanreotide Autogel® 120 mg inclusion . Patients capable give informed consent participate study agree participate signing informed consent form . Active participation interventional noninterventional acromegaly clinical study . ( Previous participation interventional observational / post marketing study ( PMS ) somatostatin analogue exclusion criterion ) . Any medical psychological condition , accord investigator judgement , might compromise ability give informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>